Ranbaxy drug recall seen hitting reputation of Indian generic companies
More than the commercial effects, industry officials are concerned that the development could have implications on the perception of the quality of drugs manufactured by Indian generic companies.
By Khomba Singh, TNN |
More than the commercial effects, industry officials are concerned that the development could have implications on the perception of the quality of drugs manufactured by Indian generic companies.
In addition, innovator companies will try to used this development to corroborate their argument that the quality of drugs manufactured in the country is suspect.
Sources close to Ranbaxy, however, downplayed the development. They pointed out that recalls are common in the global pharma industry and several drug discovery companies have withdrawn their products in the past.
Moreover, they pointed out that Ranbaxy has acted as a responsible corporate and voluntarily withdrawn the product.
Earlier this year, Novartis recalled Zelnorm used to treat irritable bowel syndrome from many global markets including the US, while Glaxosmithkline stopped selling its diabetes drug Avandia.
Industry sources say the current move is a result of the increased post- marketing surveillance of the USFDA, and other generic companies, including those from India, may face a similar situation.
In addition, innovator companies will try to used this development to corroborate their argument that the quality of drugs manufactured in the country is suspect.
Sources close to Ranbaxy, however, downplayed the development. They pointed out that recalls are common in the global pharma industry and several drug discovery companies have withdrawn their products in the past.
Moreover, they pointed out that Ranbaxy has acted as a responsible corporate and voluntarily withdrawn the product.
Earlier this year, Novartis recalled Zelnorm used to treat irritable bowel syndrome from many global markets including the US, while Glaxosmithkline stopped selling its diabetes drug Avandia.
Industry sources say the current move is a result of the increased post- marketing surveillance of the USFDA, and other generic companies, including those from India, may face a similar situation.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
